Guggenheim's target price suggests a potential upside of 79.43% from the company's current price. Shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) traded up 6.36% during mid-day trading on Tuesday, hitting $8.36. AcelRx Pharmaceuticals has a one ...

ReneSola Ltd. (ADR) (NYSE:SOL) shares increased 4.86% to $2.59. The company, on May 10, announced it provided modules for use in three community-scale solar power projects in Vermont in the last few months.

(Reuters) - AcelRX Pharmaceuticals Inc said its experimental treatment for post-operative pain met its main goal in a late-stage trial of patients who had undergone knee or hip replacement surgery, sending its shares up 15 percent.

AcelRx Pharmaceuticals logo Equities research analysts at Canaccord Genuity lifted their price target on shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) to $11.00 in a research note issued to investors on Wednesday, StockRatingsNetwork reports. A ...

Acelrx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.

AcelRx Pharmaceuticals Inc. (ACRX) said results from a late-stage study of its investigational treatment for the management of post-operative pain were positive.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) is currently trading at $8.44 up 30.7% in pre-market on 2310 shares traded. ACRX is trading 15.72% above its 50 day moving average and 50.19% above its 200 day moving average.

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) has seen its stock rise from about $5.25 per share in February at the time of the NASDAQ listing to around $9 per share and is one of the best performing stocks in the biotech industry this year.

AcelRx Pharmaceuticals Inc. (ACRX, $6.79, +$0.33, +5.11%) said results from a late-stage study of its investigational treatment for the management of post-operative pain were positive.

AcelRx Pharmaceuticals, Inc. ( ACRX ) is +0.42 at $6.88, with 107,763 shares traded. As reported by Zacks, the current mean recommendation for ACRX is in the "strong buy range".